Early Lung Cancer Blood Test Completes US Laboratory Validation
The CIZ1B biomarker assay is designed to complement LDCT screening by helping assess lung cancer risk and clarify indeterminate findings.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
New Research on Automated Myeloid Testing and Molecular Residual Disease to be Presented at AACR 2026
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Lung Cancer
Latest
Blood Test May Match CT for Early Lung Cancer Detection
The Mercy Halo test demonstrates performance similar to low-dose CT screening with the potential to reach underscreened populations.
Circulating Tumor DNA Shows Promise for Guiding Immunotherapy in Lung Cancer
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA’s potential to personalize consolidation immunotherapy decisions.
Read More
Personalis MRD Test Shows Superior Sensitivity in Lung Cancer Trial
The test demonstrated higher baseline sensitivity for ctDNA detection compared to gene mutation-based testing in AstraZeneca’s NeoADAURA study.
Read More
CyPath Lung Flags Early-Stage Cancer Overlooked by Previous Tests
A case study shows how the noninvasive test detected Stage 1A mucinous adenocarcinoma in a high-risk patient whose previous tests and follow-up scans had suggested a low probability of cancer.
Read More
Bronchoscopic Lung-Biopsy Techniques Have Fewer Complications
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
Read More
Roche Receives FDA Nod for Lung Cancer Companion Diagnostic
The FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read More
Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device
Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read More
Lung Cancer Screening Expands with New Guidelines, But Gaps Remain
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Read More
Lung Cancer Detection May Have Gotten Easier
Scientists have developed a low-cost, fast-response sensor capable of detecting lung cancer biomarkers from a blood sample in just 40 minutes.
Read More
Risk of Lung Cancer Recurrence Linked to ctDNA Levels
A new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer.
Read More
Lung Cancer Test Predicts Survival in Early Stages Better than Current Methods
The ORACLE test can predict lung cancer survival at diagnosis accurately, offering new hope for tailored treatments in stage 1 patients.
Read More
Lung Cancer Test Differentiates Malignant and Benign Nodules
The Nu.Q Cancer Test distinguished between malignant and benign pulmonary nodules detected by LDCT scans in suspected lung cancer.
Read More
AI-based Classifiers for Lung Cancer Subtyping Findings Presented
The results of AI-based classifiers for lung cancer using Qlucore Insights were recently presented by researchers.
Read More
Biofidelity’s Aspyre Lung Delivers Accurate Molecular Diagnostics for NSCLC Variants
Studies validated Biofidelity’s Aspyre Lung diagnostic tech, showcasing its ability to offer genomic profiling for actionable NSCLC variants.
Read More
Biofidelity Launches Test Offering Rapid Genomic Profiling for NSCLC Patients
Biofidelity’s test delivers comprehensive genomic profiling for NSCLC patients from tissue or liquid biopsy samples within two days.
Read More
Roche and Sheba Medical Center Partner to Improve NSCLC Diagnosis Using AI-Powered Digital Pathology
Roche and Sheba Medical Center’s ARC are collaborating to enhance NSCLC diagnosis and treatment using AI-driven digital pathology tools.
Read More